A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Transverse Myelitis (TM)
Latest Information Update: 28 Jul 2026
At a glance
- Drugs Human glial restricted progenitor cells based therapeutics (Primary)
- Indications Transverse myelitis
- Focus Adverse reactions; First in man
- Sponsors Q Therapeutics
Most Recent Events
- 21 Jul 2026 Planned End Date changed from 1 Dec 2024 to 1 Dec 2028.
- 21 Jul 2026 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2027.
- 17 Aug 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.